The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized education is essential to accommodate early career providers, community oncologists, and advanced specialists. The ACHL AdaptEd® platform achieves this by expanding and contracting to accommodate different learning needs to achieve meaningful results.
Review the rationale for targeting BCMA in the treatment of R/R MM and the mechanisms of action of BCMA-directed agents
Discuss the latest clinical data evaluating BCMA-targeted bispecific antibodies for the treatment of patients with R/R MM
Incorporate recent clinical evidence into selecting BCMA-targeted bispecific antibodies for an individual patient with heavily treated R/R MM
Develop strategies to assess individual patient risk for treatment-specific adverse events based on clinical factors when sequencing BCMA-targeted therapies in heavily treated patients
Outline the mechanisms of action and available clinical evidence with novel bispecific antibodies for R/R MM
The educational activity is directed towards hematologists, oncologists, and the multidisciplinary care team who care for/manage patients with R/R MM
Faiz Anwer, MD, FACP
Associate Professor of Medicine, Multiple Myeloma Program
Hematology, Oncology, Stem Cell Transplantation
Director, Inpatient Lymphoma Myeloma Service
Taussig Cancer Center
Cleveland Clinic
Cleveland, OH
Surbhi Sidana, MD
Assistant Professor of Medicine
Stanford Medicine
Palo Alto, CA
This CME activity was produced by Cleveland Clinic's Center for Continuing Education and Academy for Continued Healthcare Learning (ACHL).